Researchers validate preclinical effectiveness of TB drug target

In research at SRI International, scientists evaluating new drug targets against tuberculosis (TB) recently validated the preclinical effectiveness of a target that could rapidly eliminate infections and potentially shorten treatment time. The new drug target is a protein called DNA gyrase B, found in bacteria that cause TB infections.

DNA gyrase is an enzyme consisting of two subunits: gyrase A and gyrase B. Although gyrase A is often the target of antibiotics, such as ciprofloxacin, there currently is no antibiotic on the market that targets gyrase B. In laboratory experiments, SRI researchers found that by targeting gyrase B, are killed whether they are replicating or dormant. Further studies will be conducted toward the development of a TB drug against gyrase B.

"One of the greatest needs in infectious disease treatment is a drug that allows a shorter length of treatment," said Peter Madrid, Ph.D., program director in the Center for Infectious Disease and Biodefense Research, SRI Biosciences Division. "Though our program is still in the preclinical phase of research, with a number of years of required testing ahead, our goal is to develop a drug that will improve the treatment process for TB patients."

currently undergo treatment for six months and take a combination of at least four different drugs. There are often challenges to treatment effectiveness because of the long treatment time, including low patient treatment compliance and high rates of . Tuberculosis that is resistant to multiple drugs takes even longer to treat, usually 18 to 24 months.

add to favorites email to friend print save as pdf

Related Stories

Energy-saving bacteria resist antibiotics

Sep 03, 2008

Bacteria save energy by producing proteins that moonlight, having different roles at different times, which may also protect the microbes from being killed. The moonlighting activity of one enzyme from the tuberculosis bacterium ...

More molecules for tuberculosis

Mar 11, 2011

Scientists are collaborating on a new international research project to identify antibiotics that can kill tuberculosis and fight resistant strains.

Recommended for you

Dutch Ebola aid ship finishes West Africa tour

2 hours ago

The European Union says a Dutch aid ship is finishing its tour of the three West African countries hardest hit by the Ebola epidemic, docking in Liberia to deliver supplies including medical equipment.

ECOWAS trains health workers to fight Ebola

5 hours ago

West Africa's regional bloc ECOWAS said on Sunday it will train 150 health workers this week to help tackle the deadly Ebola disease in the worst hit countries; Guinea, Liberia and Sierra Leone.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.